1. Dourlen, P., Kilinc, D., Malmanche, N., Chapuis, J. & Lambert, J.-C. The new genetic landscape of Alzheimer’s disease: from amyloid cascade to genetically driven synaptic failure hypothesis? Acta Neuropathol 138, 221–236 (2019).
2. Lei, P. et al. Tau protein: relevance to Parkinson’s disease. Int J Biochem Cell Biol 42, 1775–1778 (2010).
3. Petrozziello, T. et al. Novel genetic variants in MAPT and alterations in tau phosphorylation in amyotrophic lateral sclerosis post-mortem motor cortex and cerebrospinal fluid. Brain Pathology n/a, e13035.
4. Strong, M. J., Donison, N. S. & Volkening, K. Alterations in Tau Metabolism in ALS and ALS-FTSD. Front Neurol 11, 598907 (2020).
5. Li, Y. et al. Genomics of Alzheimer’s disease implicates the innate and adaptive immune systems. Cell Mol Life Sci (2021) doi:10.1007/s00018-021-03986-5.
6. Andersen, M. S. et al. Heritability Enrichment Implicates Microglia in Parkinson’s Disease Pathogenesis. Ann Neurol 89, 942–951 (2021).
7. Keren-Shaul, H. et al. A Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease. Cell 169, 1276-1290.e17 (2017).
8. Bellenguez, C. et al. New insights on the genetic etiology of Alzheimer’s and related dementia. medRxiv 2020.10.01.20200659 (2020) doi:10.1101/2020.10.01.20200659.
9. Kunkle, B. W. et al. Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nature Genetics 51, 414–430 (2019).
10. Nalls, M. A. et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson’s disease: a meta-analysis of genome-wide association studies. The Lancet Neurology 18, 1091–1102 (2019).
11. van Rheenen, W. et al. Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nat Genet 53, 1636–1648 (2021).
12. Dhanwani, R. et al. T Cell Responses to Neural Autoantigens Are Similar in Alzheimer’s Disease Patients and Age-Matched Healthy Controls. Front Neurosci 14, 874 (2020).
13. Sulzer, D. et al. T cells from patients with Parkinson’s disease recognize α-synuclein peptides. Nature 546, 656–661 (2017).
14. Lindestam Arlehamn, C. S. et al. α-Synuclein-specific T cell reactivity is associated with preclinical and early Parkinson’s disease. Nat Commun 11, 1875 (2020).
15. Kuhn, I. et al. Serum titers of autoantibodies against α-synuclein and tau in child- and adulthood. Journal of Neuroimmunology 315, 33–39 (2018).
16. Hromadkova, L. & Ovsepian, S. V. Tau-Reactive Endogenous Antibodies: Origin, Functionality, and Implications for the Pathophysiology of Alzheimer’s Disease. J Immunol Res 2019, 7406810 (2019).
17. Holland, C. J., Cole, D. K. & Godkin, A. Re-Directing CD4(+) T Cell Responses with the Flanking Residues of MHC Class II-Bound Peptides: The Core is Not Enough. Front Immunol 4, 172 (2013).
18. Naito, T. et al. Trans-Ethnic Fine-Mapping of the Major Histocompatibility Complex Region Linked to Parkinson’s Disease. Mov Disord 36, 1805–1814 (2021).
19. Yu, E. et al. Fine mapping of the HLA locus in Parkinson’s disease in Europeans. NPJ Parkinsons Dis 7, 84 (2021).
20. Hollenbach, J. A. et al. A specific amino acid motif of HLA-DRB1 mediates risk and interacts with smoking history in Parkinson’s disease. Proc Natl Acad Sci U S A 116, 7419–7424 (2019).
21. Wightman, D. P. et al. A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer’s disease. Nat Genet 53, 1276–1282 (2021).
22. Steele, N. Z. R. et al. Fine-mapping of the human leukocyte antigen locus as a risk factor for Alzheimer disease: A case-control study. PLoS Med 14, e1002272 (2017).
23. Lindestam Arlehamn, C. S. et al. Widespread Tau-Specific CD4 T Cell Reactivity in the General Population. J Immunol 203, 84–92 (2019).
24. Zheng, X. et al. HIBAG—HLA genotype imputation with attribute bagging. Pharmacogenomics J 14, 192–200 (2014).
25. Matsuki, K. et al. DQ (rather than DR) gene marks susceptibility to narcolepsy. Lancet 339, 1052 (1992).
26. Foo, J. N. et al. Identification of Risk Loci for Parkinson Disease in Asians and Comparison of Risk Between Asians and Europeans: A Genome-Wide Association Study. JAMA Neurol 77, 746–754 (2020).
27. Kang, S. et al. Potential Novel Genes for Late-Onset Alzheimer’s Disease in East-Asian Descent Identified by APOE-Stratified Genome-Wide Association Study. J Alzheimers Dis 82, 1451–1460 (2021).
28. Shigemizu, D. et al. Ethnic and trans-ethnic genome-wide association studies identify new loci influencing Japanese Alzheimer’s disease risk. Transl Psychiatry 11, 151 (2021).
29. Loesch, D. P. et al. Characterizing the Genetic Architecture of Parkinson’s Disease in Latinos. Ann Neurol 90, 353–365 (2021).
30. Kunkle, B. W. et al. Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel: A Meta-analysis. JAMA Neurol 78, 102 (2021).
31. Jun, G. R. et al. Transethnic genome-wide scan identifies novel Alzheimer’s disease loci. Alzheimers Dement 13, 727–738 (2017).
32. Yamamoto, F. et al. Capturing Differential Allele-Level Expression and Genotypes of All Classical HLA Loci and Haplotypes by a New Capture RNA-Seq Method. Front Immunol 11, 941 (2020).
33. Grifoni, A. et al. Characterization of Magnitude and Antigen Specificity of HLA-DP, DQ, and DRB3/4/5 Restricted DENV-Specific CD4+ T Cell Responses. Front Immunol 10, 1568 (2019).
34. Schneider, J. A. et al. Cognitive impairment, decline and fluctuations in older community-dwelling subjects with Lewy bodies. Brain 135, 3005–3014 (2012).
35. Besser, L. M. et al. The revised national Alzheimer’s coordinating center’s neuropathology form-available data and new analyses. Journal of Neuropathology and Experimental Neurology 77, 717–726 (2018).
36. Cocoros, N. M. et al. Long-term Risk of Parkinson Disease Following Influenza and Other Infections. JAMA Neurology 78, 1461–1470 (2021).
37. Raposo, B. et al. T cells specific for post-translational modifications escape intrathymic tolerance induction. Nat Commun 9, 353 (2018).
38. Singhania, A. et al. The TCR repertoire of α-synuclein-specific T cells in Parkinson’s disease is surprisingly diverse. Sci Rep 11, 302 (2021).
39. Lindestam Arlehamn, C. S. et al. α-Synuclein-specific T cell reactivity is associated with preclinical and early Parkinson’s disease. Nat Commun 11, 1875 (2020).
40. Gate, D. et al. Clonally expanded CD8 T cells patrol the cerebrospinal fluid in Alzheimer’s disease. Nature 577, (2020).
41. Wesseling, H. et al. Tau PTM Profiles Identify Patient Heterogeneity and Stages of Alzheimer’s Disease. Cell 183, 1699-1713.e13 (2020).
42. He, H., Liu, Y., Sun, Y. & Ding, F. Misfolding and Self-Assembly Dynamics of Microtubule-Binding Repeats of the Alzheimer-Related Protein Tau. J Chem Inf Model 61, 2916–2925 (2021).
43. Inouye, H., Sharma, D., Goux, W. J. & Kirschner, D. A. Structure of Core Domain of Fibril-Forming PHF/Tau Fragments. Biophysical Journal 90, 1774–1789 (2006).
44. Scally, S. W. et al. A molecular basis for the association of the HLA-DRB1 locus, citrullination, and rheumatoid arthritis. J Exp Med 210, 2569–2582 (2013).
45. Ting, Y. T. et al. The interplay between citrullination and HLA-DRB1 polymorphism in shaping peptide binding hierarchies in rheumatoid arthritis. J Biol Chem 293, 3236–3251 (2018).
46. Kim, Y.-C. & Jeong, B.-H. In Silico Evaluation of Acetylation Mimics in the 27 Lysine Residues of Human Tau Protein. Curr Alzheimer Res 16, 379–387 (2019).
47. Trzeciakiewicz, H. et al. An HDAC6-dependent surveillance mechanism suppresses tau-mediated neurodegeneration and cognitive decline. Nat Commun 11, 5522 (2020).
48. Ganguly, P. et al. Tau assembly: the dominant role of PHF6 (VQIVYK) in microtubule binding region repeat R3. J Phys Chem B 119, 4582–4593 (2015).
49. Guru KrishnaKumar, V., Baweja, L., Ralhan, K. & Gupta, S. Carbamylation promotes amyloidogenesis and induces structural changes in Tau-core hexapeptide fibrils. Biochim Biophys Acta Gen Subj 1862, 2590–2604 (2018).
50. Vaquer-Alicea, J., Diamond, M. I. & Joachimiak, L. A. Tau strains shape disease. Acta Neuropathol 142, 57–71 (2021).
51. Arakhamia, T. et al. Posttranslational Modifications Mediate the Structural Diversity of Tauopathy Strains. Cell 180, 633-644.e12 (2020).
52. Park, S., Lee, J. H., Jeon, J. H. & Lee, M. J. Degradation or aggregation: the ramifications of post-translational modifications on tau. BMB Rep 51, 265–273 (2018).
53. Shin, M.-K. et al. Reducing acetylated tau is neuroprotective in brain injury. Cell 184, 2715-2732.e23 (2021).
54. Kontaxi, C., Piccardo, P. & Gill, A. C. Lysine-Directed Post-translational Modifications of Tau Protein in Alzheimer’s Disease and Related Tauopathies. Front Mol Biosci 4, 56 (2017).
55. Wesseling, H. et al. Tau PTM Profiles Identify Patient Heterogeneity and Stages of Alzheimer’s Disease. Cell 183, 1699-1713.e13 (2020).
56. Acosta, D. M., Mancinelli, C., Bracken, C. & Eliezer, D. Post-translational modifications within tau paired helical filament nucleating motifs perturb microtubule interactions and oligomer formation. Journal of Biological Chemistry 0, (2021).
57. Panda, C. et al. Aggregated Tau-PHF6 (VQIVYK) Potentiates NLRP3 Inflammasome Expression and Autophagy in Human Microglial Cells. Cells 10, 1652 (2021).
58. Carmona-Abellan, M. et al. Microglia is associated with p-Tau aggregates in the olfactory bulb of patients with neurodegenerative diseases. Neurol Sci 42, 1473–1482 (2021).
59. Irwin, D. J. et al. Acetylated tau, a novel pathological signature in Alzheimer’s disease and other tauopathies. Brain 135, 807–818 (2012).
60. Flores-Rodríguez, P. et al. The relationship between truncation and phosphorylation at the C-terminus of tau protein in the paired helical filaments of Alzheimer’s disease. Frontiers in Neuroscience 9, 33 (2015).
61. Jabbari, E. et al. Genetic determinants of survival in progressive supranuclear palsy: a genome-wide association study. Lancet Neurol 20, 107–116 (2021).
62. Sankaranarayanan, S. et al. Passive immunization with phospho-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy models. PLoS One 10, e0125614 (2015).
63. Šimić, G. et al. Tau Protein Hyperphosphorylation and Aggregation in Alzheimer’s Disease and Other Tauopathies, and Possible Neuroprotective Strategies. Biomolecules 6, 6 (2016).
64. Beecham, G. W. et al. The Alzheimer’s Disease Sequencing Project: Study design and sample selection. Neurol Genet 3, e194 (2017).
65. Bennett, D. A. et al. Overview and findings from the rush Memory and Aging Project. Current Alzheimer research 9, 646–63 (2012).
66. Le Guen, Y. et al. APOE missense variant R145C is associated with increased Alzheimer’s disease risk in African ancestry individuals with the APOE ε3/ε4 genotype. 2021.10.20.21265141 https://www.medrxiv.org/content/10.1101/2021.10.20.21265141v1 (2021) doi:10.1101/2021.10.20.21265141.
67. Kang, S. et al. Potential Novel Genes for Late-Onset Alzheimer’s Disease in East-Asian Descent Identified by APOE-Stratified Genome-Wide Association Study. J Alzheimers Dis 82, 1451–1460 (2021).
68. Satake, W. et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson’s disease. Nat Genet 41, 1303–1307 (2009).
69. Bennett, D. A. et al. Overview and findings from the rush Memory and Aging Project. Current Alzheimer research 9, 646–63 (2012).
70. Kunkle, B. W. et al. Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nature Genetics 51, 414–430 (2019).
71. Najar, J. et al. Polygenic risk scores for Alzheimer’s disease are related to dementia risk in APOE ɛ4 negatives. Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 13, e12142 (2021).
72. Gogarten, S. M. et al. Genetic association testing using the GENESIS R/Bioconductor package. Bioinformatics 35, 5346–5348 (2019).
73. Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics 26, 2190–2191 (2010).
74. Giambartolomei, C. et al. Bayesian Test for Colocalisation between Pairs of Genetic Association Studies Using Summary Statistics. PLOS Genetics 10, e1004383 (2014).
75. van Rheenen, W. et al. Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nat Genet 53, 1636–1648 (2021).
76. Lim, J., Bae, S.-C. & Kim, K. Understanding HLA associations from SNP summary association statistics. Sci Rep 9, 1337 (2019).
77. Luo, G. et al. Autoimmunity to hypocretin and molecular mimicry to flu in type 1 narcolepsy. PNAS 115, E12323–E12332 (2018).